Phase I study of the MEK1/2 inhibitor selumetinib (AZD6244) hydrogen sulfate in children and young adults with neurofibromatosis type 1 (NF1) and inoperable plexiform neurofibromas (PNs).
Brigitte C. Widemann
No relevant relationships to disclose
Leigh Jessica Marcus
No relevant relationships to disclose
Michael J. Fisher
No relevant relationships to disclose
Brian D. Weiss
No relevant relationships to disclose
AeRang Kim
No relevant relationships to disclose
Eva Dombi
No relevant relationships to disclose
Andrea Baldwin
No relevant relationships to disclose
Patricia Whitcomb
No relevant relationships to disclose
Staci Martin
No relevant relationships to disclose
Andrea Gillespie
No relevant relationships to disclose
Austin Doyle
No relevant relationships to disclose